In 1991, Dr. Nikolaus Grubhofer began research to realize his vision. He had decided to develop a better adjuvant, which meant achieving Freund's adjuvant as a benchmark for efficacy, making it perfectly biocompatible, simplifying handling, maintaining a reasonable price, and patenting and licensing it. Many data and formulations have been published as a result of Freund's 50 years of research. The problem with all of this work was that it was conducted almost exclusively with mice and was of limited use in larger animals—the necessary models for veterinary and human vaccination.

By 2001, the GERBU Adjuvant (GAD) formulations were essentially complete: a microsuspension of cationized solid lipid particles in water combined with GMDP and other excipients. They could be easily mixed with the antigen solution and were just as effective as Freund's, even in sheep, goats, cattle, and humans – but without the disadvantages: They were completely biocompatible and easy to use, suitable for a wide range of applications, including licensing for pharmaceutical purposes.

After more than 30 years of development and field trials, GAD has emerged as the only efficient, biocompatible, practical, and economical successor to adjuvants such as Freund's, Montanide, or Alumina. GERBU ADJUVANTS – powerful enhancers of the cellular and humoral immune response with long-term protective effects. Highly stable and well-tolerated. Simply mix with antigen and inject.